[144] Goldman Sachs Group Inc. SEC Filing
Rhea-AI Filing Summary
The filing is a Form 144 notice from a person connected to The Goldman Sachs Group, Inc. to sell 9,244 shares of the issuer's common stock on the NYSE with an aggregate market value of $6,923,293.80. The securities were acquired and are to be sold on 08/27/2025 as part of employee compensation awards from The Goldman Sachs Group, Inc. The filing reports no other sales in the past three months and includes the signer’s representation that they have no undisclosed material adverse information.
Positive
- Timely disclosure of the proposed sale meeting Rule 144 reporting requirements
- Transaction tied to employee compensation awards, clarifying the acquisition source
- Broker identified (Goldman Sachs & Co. LLC) and marketplace specified (NYSE)
- No sales in past three months reported for the selling person
Negative
- Insider sale of company stock (9,244 shares) could be interpreted negatively by some investors despite small size
- Limited information — the filing contains no context on vesting, taxation, or whether a 10b5-1 plan applies
Insights
TL;DR: Small, routine insider sale tied to employee compensation; disclosure ensures regulatory compliance but is immaterial to capitalization.
The filing documents a proposed sale of 9,244 shares acquired and to be sold on 08/27/2025 under employee compensation awards, placed through Goldman Sachs & Co. LLC on the NYSE. Relative to the 302,721,092 shares outstanding, the stake represents roughly 0.003%, indicating the transaction is immaterial to overall equity structure. Disclosure is timely and follows Rule 144 requirements; no prior sales in the past three months are reported. No new financial results, governance changes, or material events are included.
TL;DR: Filing appears procedurally complete and limits compliance risk; provides standard attestations about undisclosed material information.
The notice includes required seller attestations and identifies the broker, nature of acquisition, and sale date, which reduces regulatory execution risk. Because the shares were acquired as employee compensation and the filing reports no aggregated recent sales, the disclosure aligns with Rule 144 mechanics. There is no indication of material adverse information or other risk events in this document.